PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Adjunctive Cariprazine Shifts More MDD Patients Into Lower Severity Categories

cariprazineatypical antipsychoticdopamine D3-preferring partial agonistadjunctive therapymajor depressive disordertreatment-resistant depressionrandomized controlled trialpost hoc analysisMADRSpsychiatrypsychopharmacology Psychiatry / Psychopharmacology

Background Information

Cariprazine shows promise in boosting depression treatment efficacy.

Many patients with major depressive disorder (MDD) do not achieve adequate symptom relief with antidepressants alone, necessitating effective adjunctive treatments. Adjunctive cariprazine improved depressive symptom severity categories more than placebo, with 68% showing at least a one-category improvement. As a post hoc analysis, the findings support cariprazine's potential as an adjunctive treatment, but further studies are needed for definitive conclusions. Cariprazine may enhance symptom improvement for MDD patients insufficiently managed on antidepressants alone.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Masand PS, Chen C, Adams JL, Kramer K, Kerolous M

Citation: Masand PS, Chen C, Adams JL, et al. Categorical Improvement in Depressive Symptom Severity: Results From a Randomized Controlled Trial of Cariprazine for Adjunctive Treatment of MDD. CNS spectrums. 2023;28(2):245. doi:10.1017/S1092852923001803

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.